Track topics on Twitter Track topics that are important to you
Omeros reported a $14.4 million net loss, or $0.33 per share, in the second quarter of 2017 compared with a net loss of $12.6 million, or $0.32 per share, in 2016’s second quarter.Total revenues increased from $10 million a year ago to $17.2 million, all related to sales of Omidria, according to a company press release. Omidria revenue increased 40% on a sequential quarter-over-quarter basis.
Original Article: Omeros reports $14.4 million loss in second quarterNEXT ARTICLE
The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...